Screening hepatitidy D je významný i v České republice.
| Title in English | Hepatitis D screening is important in the Czech Republic as well. |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Klinická mikrobiologie a infekční lékařství |
| MU Faculty or unit | |
| Citation | |
| Keywords | hepatitis D virus (HDV); hepatitis D; HDV screening; pegylated interferon-alpha; bulevirtide |
| Description | Only patients infected with hepatitis B virus (HBV) can contract hepatitis D virus (HDV) infection - HDV is acquired simultaneously (co-infection) or as a superinfection in those already infected with HBV. Routes of HDV transmission are contaminated needles or transfusion; sexual and vertical transmission are relatively rare. Chronic hepatitis D is the most serious form of chronic viral hepatitis due to more rapid progression to decompensated cirrhosis and hepatocellular carcinoma (HCC) than the other forms of chronic viral hepatitis. Liver cirrhosis can developed in 5 years and HCC in 10 years of dual infection. I most cases HDV suppressed HBV replication. It leads to positivity of HDV nucleic acid (HDV RNA) and negativity or low level of HBV nucleic acid (HBV DNA) in plasma in most patients. At present there is not routine screening of HDV in persons with chronic HBV infection in the Czech Republic. One of the reasons is reduced motivation to screen due to no approved treatment options until recently. The only one possibility of treatment is administration of pegylated interferon (PEG-IFN)-? for 48 weeks or even more. This therapy is without long-term efficacy in most cases. Therapy with bulevirtide seems to be perspective but it has not been approved in the Czech Republic yet. |